Trial Profile
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2022
Price :
$35
*
At a glance
- Drugs CJM 112 (Primary)
- Indications Hidradenitis suppurativa
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 01 Oct 2022 Primary endpoint has been met (Clinical responder rate; proportion of study participants achieving a clinical response in Hidradenitis Suppurativa - Physician Global Assessment score) , according to Results published in the Experimental Dermatology
- 01 Oct 2022 Results published in the Experimental Dermatology
- 13 Dec 2016 Status changed from active, no longer recruiting to completed.